GAMT, the third OTC supplement treatment

The treatment for guanidinoacetate methyltransferase deficiency is creatine. Creatine is a supplement sold in any sporting goods store and most pharmacies. Combined with ornithine and a low-arginine diet, daily oral creatine supplementation prevents the intellectual disability, autism, seizures, and movement disorders that define untreated GAMT deficiency. The condition is the third on the US Recommended Uniform Screening Panel, after biotinidase and the partial response in some HLCS, where the disease-modifying therapy is something a family can buy without a prescription.

The case for screening is the same case those other two conditions made: a treatable disorder with a catastrophic untreated course, a reliable dried blood spot assay, and a treatment that is biologically straightforward and remarkably inexpensive when started early.

What GAMT is

GAMT deficiency is an autosomal recessive cerebral creatine deficiency syndrome caused by variants in GAMT on chromosome 19p13. GAMT catalyzes the second of two steps in creatine biosynthesis. The first enzyme, AGAT (encoded by GATM), produces guanidinoacetate from arginine and glycine. GAMT then methylates guanidinoacetate to creatine using S-adenosylmethionine as the methyl donor. When GAMT activity fails, guanidinoacetate accumulates and creatine production collapses.

The clinical consequence is dual. Creatine deficiency in the brain produces the encephalopathy, since creatine and phosphocreatine support neuronal energy buffering. Guanidinoacetate accumulation produces additional toxicity, with documented effects on GABAergic signaling that may contribute to the seizure phenotype.

The clinical picture in untreated GAMT includes intellectual disability of variable severity, autism-spectrum features, seizures (often pharmacoresistant), extrapyramidal movement disorders, and sometimes behavioral disturbance. Onset is typically in infancy or early childhood. Without treatment, most affected individuals have lifelong substantial disability.

GAMT deficiency was first described in 1994. The condition has only been recognized for three decades, which means a substantial number of older people with intellectual disability of unknown cause may have undiagnosed GAMT deficiency. Retrospective screening of institutionalized populations has identified previously undiagnosed cases. The hidden-population issue is documented but not systematically addressed.

Reported live-birth incidence is roughly 1 in 250,000 to 1 in 500,000 in screened populations.

Detection

GAMT deficiency was added to the federal Recommended Uniform Screening Panel in 2023. The screening marker is guanidinoacetate, GAA, on the dried blood spot, with second-tier testing including plasma creatine, urinary creatine and GAA, and GAMT sequencing. Brain MR spectroscopy in symptomatic individuals shows the characteristic absence of the creatine peak.

The two other cerebral creatine deficiency syndromes, AGAT deficiency and creatine transporter deficiency (X-linked), have overlapping clinical features but different biochemical signatures and different treatment responses. Distinguishing the three is part of the workup.

What management looks like

Standard of care for GAMT deficiency is oral creatine monohydrate at pharmacological doses, typically 400 to 800 mg per kg per day in divided doses, plus ornithine supplementation and a low-arginine diet. Ornithine competes with arginine for the AGAT enzyme, reducing guanidinoacetate production. The low-arginine diet further reduces guanidinoacetate accumulation by limiting substrate supply. The combination addresses both the creatine deficit and the guanidinoacetate excess.

Children identified by newborn screening and started on the combined regimen in the first weeks of life have substantially preserved cognitive and motor outcomes. Cohort data from screen-detected children, while still limited because the condition is rare and screening is recent, shows normal or near-normal development at school age in most cases. Children identified clinically after symptoms have developed have partial response: seizures often improve, movement disorder often improves, but established intellectual disability and autism-spectrum features improve less.

The cost-effectiveness arithmetic mirrors biotinidase deficiency. Lifetime supplement and dietary costs are modest. Lifetime cost of unrecognized GAMT deficiency is the cost of lifelong cognitive and behavioral disability. The screening case is therefore a clean cost-saving case in addition to the clinical-benefit case.

What this looks like for a family

A baby is born and the heel-prick is sent. On day 5, the state lab reports an elevated guanidinoacetate. On day 7, plasma creatine and urine GAA confirm the biochemical pattern, and GAMT sequencing returns biallelic pathogenic variants. The metabolic team starts oral creatine, ornithine, and the low-arginine diet within the first weeks of life. The metabolic dietitian provides protein-restriction guidance compatible with normal growth. Brain MR spectroscopy at intervals tracks the creatine peak.

That child grows up with normal or near-normal cognitive development, attending a typical school, taking a few grams of an over-the-counter supplement every day, eating a moderately protein-restricted diet under metabolic supervision. Without screening, the same child would have been identified at age 4 or 5 with developmental regression, autism-spectrum features, and seizures, and the supplements that would have been the disease-modifying therapy at birth would have been only partial therapy after the developmental window had largely closed.

The screen rewrote the timeline. The treatment is on the shelf at a sporting goods store.